Scarica l'app Stockscreener
2.39
5.16%
-0.13
Dopo l'orario di chiusura:
2.31
-0.08
-3.35%
Precedente Chiudi:
$2.52
Aprire:
$2.67
Volume 24 ore:
23,607
Relative Volume:
0.31
Capitalizzazione di mercato:
$3.66M
Reddito:
-
Utile/perdita netta:
$-12.30M
Rapporto P/E:
-0.3716
EPS:
-6.4313
Flusso di cassa netto:
$-11.13M
1 W Prestazione:
-4.02%
1M Prestazione:
-38.56%
6M Prestazione:
-62.42%
1 anno Prestazione:
-73.66%
Intervallo 1D:
$2.3308
$2.67
Intervallo di 1 settimana:
$2.20
$2.67
Portata 52W:
$2.18
$22.35
Palisade Bio Inc Stock (PALI) Company Profile
Nome
Palisade Bio Inc
Settore
Industria
Telefono
(858) 704-4900
Indirizzo
7750 EL CAMINO REAL, SUITE 5200, CARLSBAD
Confronta PALI con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
| PALI | 2.39 | 3.66M | 0 | -12.30M | -11.13M | -6.4313 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Palisade Bio Inc Borsa (PALI) Ultime notizie
ARMISTICE CAPITAL, LLC Acquires Shares in Palisade Bio Inc - GuruFocus.com
Palisade Bio CMO Mitch Jones, MD, PhD, to Present at 8th Annual Antifibrotic Drug Development (AFDD) Summit - The Manila Times
Contrasting Palisade Bio (NASDAQ:PALI) & Anavex Life Sciences (NASDAQ:AVXL) - Defense World
Palisade Bio Reports Third Quarter 2024 Financial Results - GlobeNewswire
Palisade Bio Advances UC Drug Trial: Key Phase 1 Milestones & Patent Wins Boost Pipeline | PALI Stock News - StockTitan
Palisade Bio initiates phase 1 study of new UC drug - Investing.com
Palisade Bio initiates phase 1 study of new UC drug By Investing.com - Investing.com Australia
Palisade Bio Announces First Subject Dosed in Phase 1 Clinical Study of PALI-2108 for the Treatment of Moderate-to-Severe Ulcerative Colitis (UC) - The Manila Times
Intelligent Bio Solutions Reports Fiscal 2025 First Quarter Financial Results and Operational Highlights - The Manila Times
Palisade Bio Announces First Subject Dosed in Phase 1 - GlobeNewswire
Palisade Bio Launches Phase 1 Trial for Novel Ulcerative Colitis Drug PALI-2108 | PALI Stock News - StockTitan
Palisade Bio (NASDAQ:PALI) and Allogene Therapeutics (NASDAQ:ALLO) Critical Survey - Defense World
Palisade Bio advances novel IBD treatment PALI-2108 - Investing.com
Palisade Bio advances novel IBD treatment PALI-2108 By Investing.com - Investing.com UK
HYCU® Recognized as CRN 2024 Product of the Year Finalist - The Manila Times
Palisade Bio Announces Positive Data from Two Ex Vivo - GlobeNewswire
Palisade Bio Announces Positive Data from Two Ex Vivo Translational Studies of PALI-2108 for the Treatment of Ulcerative Colitis - StockTitan
PALI stock touches 52-week low at $3.09 amid market fluctuations - Investing.com
Alto Neuroscience’s depression drug trial fails at phase 2 - BioPharma-Reporter.com
Alto Neuroscience’s Depression Trial Failure Sends Shares Into Downward Spiral - MedCity News
Palisade Bio Announces Abstract Accepted for Presentation - GlobeNewswire
Palisade Bio Announces Abstract Accepted for Presentation at the American College of Gastroenterology's (ACG) 2024 Annual Scientific Meeting - The Manila Times
Sutro Biopharma (NASDAQ:STRO) & Palisade Bio (NASDAQ:PALI) Head-To-Head Contrast - Defense World
Meta Platforms (NASDAQ:META) Shares Up 0.6% Following Analyst Upgrade - Defense World
Palisade Bio receives Health Canada nod for UC drug trial By Investing.com - Investing.com Australia
Palisade Bio receives Health Canada nod for UC drug trial - Investing.com
Palisade Bio Cleared by Health Canada to Commence Phase 1 - GlobeNewswire
Palisade Bio Cleared by Health Canada to Commence Phase 1 Clinical Study for Lead Program, PALI-2108 for the Treatment of Ulcerative Colitis (UC) - Yahoo Finance
Palisade Bio to Participate in the 2024 Maxim Healthcare Virtual Summit, Presented by Maxim Group LLC - The Manila Times
Pre-market Movers: GANX, TFFP, AKYA, CLDI... - RTTNews
Palisade Bio, Inc. (NASDAQ:PALI) Shares Sold by Armistice Capital LLC - Defense World
Palisade Bio inks new deal with CEO Finley; terms disclosed By Investing.com - Investing.com Canada
Palisade Bio inks new deal with CEO Finley; terms disclosed - Investing.com India
Palisade Bio CEO Finley’s Revised Employment and Compensation Deal - TipRanks
Palisade submits CTA for PDE4 inhibitor prodrug for ulcerative colitis - BioWorld Online
PALI stock touches 52-week low at $3.3 amid market fluctuations - Investing.com UK
PALIPalisade Bio, Inc. Latest Stock News & Market Updates - StockTitan
Palisade Bio Provides Update on Progress Toward Launch of - GlobeNewswire
Palisade Bio Provides Update on Progress Toward Launch of Phase 1 Human Clinical Study for Lead Program, PALI-2108 for the Treatment of Ulcerative Colitis - StockTitan
Klea Holding Evaluates Generous Takeover Offer - TipRanks
The growth track for Kura Oncology Inc (KURA) has changed recently - SETE News
Potential Price Increase for Kulicke & Soffa Industries, Inc. (KLIC) After Recent Insider Activity - Knox Daily
Big Changes At Disney Animation: Jennifer Lee Steps Down And Jared Bush Steps In - mxdwn.com
116,268 Shares in Proficient Auto Logistics, Inc. (NASDAQ:PAL) Purchased by First Eagle Investment Management LLC - MarketBeat
Angelina Jolie overwhelmed by ‘beautiful feeling’ of motherhood - FemaleFirst
Anitra (AMEX:AZTR) Stock Quotes, Forecast and News Summary - Benzinga
Palisade Bio (NASDAQ:PALI) Stock Quotes, Forecast and News Summary - Benzinga
Proficient Auto Logistics (NASDAQ:PAL) Earns "Outperform" Rating from Barrington Research - MarketBeat
Jared Bush Taking Over Jennifer Lee’s Role As Walt Disney Animation Studios Chief Creative Officer - What's On Disney Plus
Alaska Air completes acquisition of Hawaiian Airlines - The Seattle Times
Bokf Na Has $58,000 Stock Position in Haleon plc (NYSE:HLN) - Defense World
Palisade Bio Inc Azioni (PALI) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.66%
1.11%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):